Literature DB >> 17210620

G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Carles Gaig1, María José Martí, Mario Ezquerra, Maria Jesús Rey, Adriana Cardozo, Eduardo Tolosa.   

Abstract

The G2019S leucine-rich repeat kinase 2 gene (LRRK2) mutation has been identified in a significant proportion of familial and sporadic cases of Parkinson's disease (PD). Until now, information on the neuropathological changes associated with the G2019S LRRK2 mutation has been sparse. We report a 77-year-old patient who presented with a 14 year history of PD but, unexpectedly, histopathological examination disclosed mild neuronal loss in the substantia nigra without alpha-synuclein, tau or ubiquitin cytoplasmic inclusions. A G2019S LRRK2 mutation was eventually detected. The present case confirms that clinical PD caused by G2019S mutations can be associated with non-specific nigral degeneration without Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210620      PMCID: PMC2077973          DOI: 10.1136/jnnp.2006.107904

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy.

Authors:  K Hasegawa; H Kowa
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

3.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

Authors:  William C Nichols; Nathan Pankratz; Dena Hernandez; Coro Paisán-Ruíz; Shushant Jain; Cheryl A Halter; Veronika E Michaels; Terry Reed; Alice Rudolph; Clifford W Shults; Andrew Singleton; Tatiana Foroud
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

4.  LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.

Authors:  Carles Gaig; Mario Ezquerra; Maria Jose Marti; Esteban Muñoz; Francesc Valldeoriola; Eduardo Tolosa
Journal:  Arch Neurol       Date:  2006-03

5.  Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers.

Authors:  Thomas G Beach; Douglas G Walker; Lucia I Sue; Amanda Newell; Charles C Adler; Jeffrey N Joyce
Journal:  J Neuropathol Exp Neurol       Date:  2004-04       Impact factor: 3.685

6.  Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q.

Authors:  H Mori; T Kondo; M Yokochi; H Matsumine; Y Nakagawa-Hattori; T Miyake; K Suda; Y Mizuno
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

7.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

8.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Authors:  Alessio Di Fonzo; Cristina Tassorelli; Michele De Mari; Hsin F Chien; Joaquim Ferreira; Christan F Rohé; Giulio Riboldazzi; Angelo Antonini; Gianni Albani; Alessandro Mauro; Roberto Marconi; Giovanni Abbruzzese; Leonardo Lopiano; Emiliana Fincati; Marco Guidi; Paolo Marini; Fabrizio Stocchi; Marco Onofrj; Vincenzo Toni; Michele Tinazzi; Giovanni Fabbrini; Paolo Lamberti; Nicola Vanacore; Giuseppe Meco; Petra Leitner; Ryan J Uitti; Zbigniew K Wszolek; Thomas Gasser; Erik J Simons; Guido J Breedveld; Stefano Goldwurm; Gianni Pezzoli; Cristina Sampaio; Egberto Barbosa; Emilia Martignoni; Ben A Oostra; Vincenzo Bonifati
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

9.  Parkin disease: a phenotypic study of a large case series.

Authors:  Naheed L Khan; Elizabeth Graham; Peter Critchley; Anette E Schrag; Nicholas W Wood; Andrew J Lees; Kailash P Bhatia; Niall Quinn
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  49 in total

Review 1.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

2.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

3.  Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Authors:  R Saunders-Pullman; K Stanley; C Wang; M San Luciano; V Shanker; A Hunt; L Severt; D Raymond; L J Ozelius; R B Lipton; S B Bressman
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

4.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

Review 5.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

6.  Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Miguel Verbitsky; Sergey Kisselev; Barbara M Ross; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Elise Caccappolo; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  Arch Neurol       Date:  2009-12

Review 7.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

10.  Genetic neuropathology of Parkinson's disease.

Authors:  Mark R Cookson; John Hardy; Patrick A Lewis
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.